Given a passage with a question and an answer to that question, classify if the answer actually answers the question into 'yes' or 'no'. Output 'yes' if the answer answers the question and output 'no' if the answer does not answer the question.

Q: Question: Do nAT1 genotypes predict response to mesalamine in patients with ulcerative colitis?
Answer: NAT1 genotypes do not predict response or side effects to mesalamine in patients with UC. Variations caused by non-genomic effects may be associated with the clinical response to 5-ASA.

A: no
****
Q: Question: Are antihelminthic benzimidazoles novel HIF activators that prevent oxidative neuronal death via binding to tubulin?
Answer: These studies demonstrate that tubulin-binding drugs can activate a component of the hypoxic adaptive response, specifically the stabilization of HIF-1 and its downstream targets. Tubulin-binding drugs, including antihelminthic benzimidazoles, also abrogate oxidative neuronal death in primary neurons. Given their safety in humans and known ability to penetrate into the central nervous system, antihelminthic benzimidazoles may be considered viable candidates for treating diseases associated with oxidative neuronal death, including stroke.

A: yes
****
Q: Question: Does g-8 indicate overall and quality-adjusted survival in older head and neck cancer patients treated with curative radiochemotherapy?
Answer: G-8 is indicative of quality-adjusted survival, and should be considered at time of treatment decisions for the older HNCA patient.

A:
yes
****